FluidForm Bio, Inc.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2026 | $2 M | No. 1 | Under $2 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
FluidForm Bio, Inc. reported revenue of $168,783 for its most recent fiscal year (filed Apr 2025), down from $1.95 million the year before.
SEC Form C · Apr 2025
The direct cost of what it sold was $24,150, so 86% of its revenue was left after those costs.
SEC Form C · Apr 2025
Net loss for the same year: $4.39 million.
SEC Form C · Apr 2025
FluidForm Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2026).
SEC Form D · Aug 2026
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2026
In its own words
How the company describes itself to search engines on its website, word for word.
“We build living human tissue using cells, proteins, and nothing else. Our technology leverages the intersection of personalized medicine, synthetic and computational biology, advanced materials, bioprinting, and AI to go from patient data to human tissue.”
Source: The company's website · as of Nov 15, 2026
Products and services#
No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.
Investors#
No investor of FluidForm Bio, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 20 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Adam Feinberg | Chief Technology Officer | Aug 2026 |
| Erik Waters | Chief Financial Officer | Aug 2026 |
| Michael Graffeo | President and Chief Executive Officer | Aug 2026 |
| Adam Feinberg | Chief Technology Officer | Aug 2026 |
| Michael Graffeo | President and Chief Executive Officer | Aug 2026 |